ATE201866T1 - Morpholinderivate und ihre verwendung als therapeutische mittel - Google Patents

Morpholinderivate und ihre verwendung als therapeutische mittel

Info

Publication number: ATE201866T1
Authority: AT; Austria
Prior art keywords: 4alkyl; pct; hydrogen; 4alkoxy; hydroxy
Prior art date: 1994-08-15

Application number

AT95927862T

Other languages

English (en)

Inventor

Timothy Harrison

Andrew Pate Owens

Christopher John Swain

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-15

Filing date

1995-08-07

Publication date

2001-06-15

1994-08-15 Priority claimed from GB9416427A external-priority patent/GB9416427D0/en

1995-05-11 Priority claimed from GBGB9509605.3A external-priority patent/GB9509605D0/en

1995-08-07 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2001-06-15 Application granted granted Critical

2001-06-15 Publication of ATE201866T1 publication Critical patent/ATE201866T1/de

Links

YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000006413 ring segment Chemical group 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT95927862T 1994-08-15 1995-08-07 Morpholinderivate und ihre verwendung als therapeutische mittel ATE201866T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9416427A GB9416427D0 (en)	1994-08-15	1994-08-15	Therapeutic agents
GBGB9509605.3A GB9509605D0 (en)	1995-05-11	1995-05-11	Therapeutic agents
PCT/GB1995/001868 WO1996005181A1 (en)	1994-08-15	1995-08-07	Morpholine derivatives and their use as therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE201866T1 true ATE201866T1 (de)	2001-06-15

Family

ID=26305450

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95927862T ATE201866T1 (de)	1994-08-15	1995-08-07	Morpholinderivate und ihre verwendung als therapeutische mittel

Country Status (13)

Country	Link
US (1)	US5824678A (de)
EP (1)	EP0777659B1 (de)
JP (1)	JP2002502351A (de)
AT (1)	ATE201866T1 (de)
AU (1)	AU691327B2 (de)
CA (1)	CA2195972A1 (de)
DE (1)	DE69521208T2 (de)
DK (1)	DK0777659T3 (de)
ES (1)	ES2157337T3 (de)
GR (1)	GR3036006T3 (de)
IL (1)	IL114865A (de)
PT (1)	PT777659E (de)
WO (1)	WO1996005181A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP2001504849A (ja) *	1996-12-02	2001-04-10	メルクシヤープエンドドームリミテツド	ストレス障害の治療のためのｎｋ−１受容体拮抗薬の使用
AU731674B2 (en) *	1996-12-02	2001-04-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating substance use disorders
US6613765B1 (en)	1996-12-02	2003-09-02	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating major depressive disorders
AU729708B2 (en) *	1996-12-02	2001-02-08	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating severe anxiety disorders
US6114315A (en) *	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273351A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating sexual dysfunction
AU734872B2 (en) *	1996-12-02	2001-06-21	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
WO1998024445A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating schizophrenic disorders
ATE288756T1 (de) *	1996-12-02	2005-02-15	Merck Sharp & Dohme	Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
CA2273853A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating cognitive disorders
US5977104A (en) *	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
US6100256A (en) *	1996-12-02	2000-08-08	Merck Sharp & Dohme Ltd.	Use of NK-1 receptors antagonists for treating schizophrenic disorders
DE69732133T2 (de) *	1996-12-02	2005-12-22	Merck Sharp & Dohme Ltd., Hoddesdon	Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
CA2273856A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating bipolar disorders
CA2287487A1 (en) *	1997-04-24	1998-10-29	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating eating disorders
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
WO1999007375A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
CA2298777A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating mania
US6087348A (en) *	1997-12-01	2000-07-11	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating stress disorders
US6156749A (en) *	1997-12-01	2000-12-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
US6271230B1 (en)	1997-12-01	2001-08-07	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating cognitive disorders
AU1230000A (en) *	1998-10-30	2000-05-22	Merck & Co., Inc.	Linear process for the preparation of a morpholine compound
GB9907571D0 (en)	1999-04-06	1999-05-26	Zeneca Ltd	Compounds
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7279547B2 (en) *	2000-02-10	2007-10-09	University Of Connecticut	Insecticidal compounds and methods for selection thereof
WO2001068621A1 (en)	2000-03-13	2001-09-20	Ortho-Mcneil Pharmaceutical, Inc.	Novel cyclohexene derivatives useful as antagonists of the motilin receptor
US6392040B2 (en)	2000-03-13	2002-05-21	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene compounds useful as antagonists of the motilin receptor
US6384031B2 (en)	2000-03-13	2002-05-07	Ortho-Mcneil Pharmaceutical, Inc.	Cyclobutene derivatives useful as antagonists of the motilin receptor
AU7334901A (en)	2000-07-11	2002-01-21	Du Pont Pharm Co	Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
WO2003101459A1 (en) *	2002-05-29	2003-12-11	The Regents Of The University Of California	Antagonizing nk1 receptors inhibits consumption of substances of abuse
BRPI0513359A (pt)	2004-07-15	2008-05-06	Amr Technology Inc	tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
EP1888050B1 (de)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
UA95454C2 (uk)	2005-07-15	2011-08-10	Амр Текнолоджи, Інк.	Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
EP2083831B1 (de)	2006-09-22	2013-12-25	Merck Sharp & Dohme Corp.	Verfahren zur behandlung von fettsäure-synthese-hemmern
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es)	2007-01-10	2009-04-22	Inst Di Reserche D Biolog Mole	Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
US20100105688A1 (en)	2007-01-24	2010-04-29	Glaxo Group Limited	Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
CN102638982B (zh)	2009-05-12	2015-07-08	百时美施贵宝公司	(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011901A (es)	2009-05-12	2012-01-20	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
EP2429296B1 (de)	2009-05-12	2017-12-27	Albany Molecular Research, Inc.	7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung
AU2010307198B9 (en)	2009-10-14	2014-02-13	Merck Sharp & Dohme Corp.	Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
JP6043285B2 (ja)	2010-08-02	2016-12-14	サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt)	2010-08-17	2019-07-25	Sirna Therapeutics, Inc.	Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (de)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
US8946216B2 (en)	2010-09-01	2015-02-03	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Kondensierte pyrazolderivate als neue erk-hemmer
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (de)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
EP2699568A1 (de)	2011-04-21	2014-02-26	Piramal Enterprises Limited	Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
EP3453762B1 (de)	2012-05-02	2021-04-21	Sirna Therapeutics, Inc.	Sina-zusammensetzungen
EP2900241B1 (de)	2012-09-28	2018-08-08	Merck Sharp & Dohme Corp.	Neuartige verbindungen als erk-hemmer
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
ES2707305T3 (es)	2012-12-20	2019-04-03	Merck Sharp & Dohme	Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Kreisförmige polynukleotide
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033284A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US11993602B2 (en)	2018-08-07	2024-05-28	Merck Sharp & Dohme Llc	PRMT5 inhibitors
US12173026B2 (en)	2018-08-07	2024-12-24	Merck Sharp & Dohme Llc	PRMT5 inhibitors
CN111004190A (zh) *	2019-11-08	2020-04-14	广州曼翔医药有限公司	一种阿瑞匹坦中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE136885T1 (de) *	1991-08-20	1996-05-15	Merck Sharp & Dohme	Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IL106142A (en) *	1992-06-29	1997-03-18	Merck & Co Inc	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) *	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) *	1993-12-29	2005-03-22	Raymond Baker	Substituted morpholine derivatives and their use as therapeutic agents

1995
- 1995-08-07 WO PCT/GB1995/001868 patent/WO1996005181A1/en not_active Ceased
- 1995-08-07 EP EP95927862A patent/EP0777659B1/de not_active Expired - Lifetime
- 1995-08-07 DK DK95927862T patent/DK0777659T3/da active
- 1995-08-07 AU AU31855/95A patent/AU691327B2/en not_active Ceased
- 1995-08-07 US US08/793,186 patent/US5824678A/en not_active Expired - Fee Related
- 1995-08-07 ES ES95927862T patent/ES2157337T3/es not_active Expired - Lifetime
- 1995-08-07 AT AT95927862T patent/ATE201866T1/de not_active IP Right Cessation
- 1995-08-07 PT PT95927862T patent/PT777659E/pt unknown
- 1995-08-07 CA CA002195972A patent/CA2195972A1/en not_active Abandoned
- 1995-08-07 DE DE69521208T patent/DE69521208T2/de not_active Expired - Fee Related
- 1995-08-07 JP JP50710696A patent/JP2002502351A/ja not_active Withdrawn
- 1995-08-08 IL IL11486595A patent/IL114865A/xx active IP Right Grant
2001
- 2001-06-07 GR GR20010400305T patent/GR3036006T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0777659A1 (de)	1997-06-11
ES2157337T3 (es)	2001-08-16
AU3185595A (en)	1996-03-07
AU691327B2 (en)	1998-05-14
WO1996005181A1 (en)	1996-02-22
DE69521208D1 (de)	2001-07-12
IL114865A (en)	1999-06-20
IL114865A0 (en)	1995-12-08
US5824678A (en)	1998-10-20
JP2002502351A (ja)	2002-01-22
DE69521208T2 (de)	2001-11-08
PT777659E (pt)	2001-09-28
GR3036006T3 (en)	2001-09-28
DK0777659T3 (da)	2001-09-03
CA2195972A1 (en)	1996-02-22
EP0777659B1 (de)	2001-06-06

Legal Events

Date	Code	Title	Description
2001-10-15	UEP	Publication of translation of european patent specification
2003-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE201866T1 (de)	2001-06-15	Morpholinderivate und ihre verwendung als therapeutische mittel
GB9426103D0 (en)	1995-02-22	Therapeutic agents
ATE360631T1 (de)	2007-05-15	Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE360630T1 (de)	2007-05-15	Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ES2159558T3 (es)	2001-10-16	Derivados de guanidina como inhibidores del intercambio na+/h+ en las celulas.
ATE401314T1 (de)	2008-08-15	Benzodiazepin-derivate als gamma-secretase inhibitoren
IL144236A0 (en)	2002-05-23	Tetrahydropyran derivatives and their use as therapeutic agents
ES2098947T3 (es)	1997-05-01	Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
ES2135769T3 (es)	1999-11-01	Derivados de isotiourea como inhibidores de no-sintasa.
DE69511544D1 (de)	1999-09-23	Amidderivate und ihre therapeutische verwendung
EA200500882A1 (ru)	2005-12-29	N-арилсульфонил-3-аминоалкоксииндолы
JO2231B1 (en)	2004-10-07	Derivatives of Trahydroperan and its use as a therapeutic agent
AU1799297A (en)	1997-09-02	Spiro-ketal derivatives and their use as therapeutic agents
DE69413831D1 (de)	1998-11-12	Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
SE9603284D0 (sv)	1996-09-10	New compounds